Besides, TFEB could elevate PD-L1 expressions to promote immune evasion resistance to mTOR inhibition in renal cell carcinoma, highlighting the significant relationships between TFEB and immunotherapy [49]. This evidence concerns the gene MTOR and renal cell carcinoma.